Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in duchenne muscular dystrophy patients and in dystrophin deficient rodents, Neuromuscular Disorders (2017), http://dx.doi.org/doi: 10.1016/j.nmd.2017.05.009. This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain. patients. Urinary N-ter titin was also evaluated in dystrophin deficient rodent models. Mdx mice exhibited low urinary N-ter titin levels at 2 weeks of age followed by a robust and sustained elevation starting at 3 weeks of age, coincident with the development of systemic skeletal muscle damage in this model; fold elevation could not be determined because urinary N-ter titin was not detected in age-matched wild type mice. Levels of serum creatine kinase and serum skeletal muscle troponin I (TnI) were also low at 2 weeks, elevated at later time points and were significantly correlated with urinary N-ter titin excretion in mdx mice. Corticosteroid treatment of mdx mice resulted in improved exercise performance and lowering of both urinary N-ter titin and serum skeletal muscle TnI concentrations. Low urinary N-ter titin levels were detected in wild type rats (3.0 ± 0.6 ng/ml), while Dmd mdx rats exhibited a 556-fold increase (1652.5 ± 405.7 ng/ml, P = 0.002) (both at 5 months of age). These results suggest that urinary N-ter titin is present at low basal concentrations in normal urine, and increases dramatically coincident with
Title
Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents 
Authors and affiliations

Introduction
Skeletal muscle titin (also known as connectin) is a giant protein (3.3-3.7 million Da) that functions in a spring-like mechanical fashion connecting the Z-disc to the M-line in the sarcomere. It is one of the most abundant proteins in striated muscle (reviewed in [1] ). The role of titin in normal skeletal muscle physiology is not limited to a structural connectivity-titin is crucial to the skeletal muscle modeling response to damage induced by eccentric contractions and is an important mechanosensor for hypertrophic signaling [1] . Consistent with these functional roles, degradation of titin has also been demonstrated in muscle biopsies from muscular dystrophy patients with severe skeletal muscle functional deficits [2, 3] , and titin mutations are increasingly recognized for a role in neuromuscular disorders [4] .
Non-invasive biomarkers are needed to facilitate discovery and development of new therapeutics for muscular dystrophies. Recently, a mass spectrometric proteomics analysis by
Rouillon, et al [5] showed that peptides derived from the N-terminus of the skeletal muscle titin (N-ter titin) were found in urine from Duchenne Muscular Dystrophy (DMD) subjects and represented the highest fold-change of any protein compared to urine from healthy controls.
They further showed that antibodies against N-ter titin detected a 25 kDa fragment in DMD urine as well as in urine from the mdx muscular dystrophy mouse and golden retriever muscular dystrophy dog, but not in normal animals [5] . Proteomics approaches have also detected titin in the serum of ambulant and non-ambulant DMD patients but not healthy controls [6] . One limitation of these data sets is that Western blot and proteomics approaches do not precisely quantify the extent of urinary titin elevation in human disease or animal models.
We report here the development of a sensitive conventional enzyme-linked immunosorbent assay (ELISA), and an electrochemiluminescence (ECL) assay, that can be used
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with small sample volumes and display an increased dynamic range, for the precise quantification of N-ter titin fragments in urine. Importantly, in addition to qualifying the assays using urine from DMD patients, we included normalization to urine mean specific gravity to account for hydration status differences, since the more common use of normalization to urine creatinine is not suitable for DMD patients. The natural history of urinary N-ter titin excretion was studied in the mdx mouse model and further examined in the rat Dmd mdx rat model. Our ELISA and ECL assays permitted quantitation of background levels of N-ter titin in urine of agematched healthy human and wild-type rat controls that was not possible with the less sensitive Western blot approaches [5] . The increase in sensitivity in turn permitted the quantification of the fold-elevation in urinary N-ter titin excretion in DMD patients, and the quantitative assessment of translational potential from the mdx mouse and Dmd mdx rat models. Finally, urinary N-ter titin excretion was compared to serum levels of the known markers of skeletal muscle damage, creatine kinase (CK) and skeletal muscle TnI.
Materials and Methods
DMD patient and age-matched healthy control urine samples
Anonymized frozen urine samples collected from DMD ranging in age from 3-14 years, and age-matched control male subjects, were obtained from the Newcastle MRC Centre for Neuromuscular Diseases Biobank (Newcastle University, UK), and were Research Ethics Committee (REC) approved.
Animals and biospecimen collection
All studies were conducted in accordance with the Bristol-Myers Squibb Policy on the Care, Welfare and Treatment of Laboratory Animals. All protocols were reviewed by the Animal Care and Use Committee at Bristol-Myers Squibb. C57BL/10ScSn-Dmd<mdx>/J hemizygous (mdx) male mice and C57BL/10ScSn (WT) male mice were obtained from Jackson Laboratories (Bar Harbor, ME) and further bred in the vivarium at Bristol-Myers Squibb (Wallingford, CT). For mouse urine sample collection, mice were gently restrained by gathering the skin of the neck and back to briefly hold the mouse over a hydrophobic surface. This handling was sufficient to induce urination that could be acquired as droplets, typically 5-10 l total volume. Mouse blood for preparation of serum was obtained by retro-orbital bleed.
Dmd mdx hemizygous male rats [7] and Sprague-Dawley (SD/Crl) WT male rat littermates were obtained by breeding Dmd mdx heterozygous female rats (obtained from Ignacio Anegon, INSERM, University of Nantes, Nantes, France) with WT male SD/Crl rats at Charles River (Wilmington, MA). Rat urine was collected using a metabolic cage fitted with a urine collection tube overnight, typically yielding ~15 ml total urine volume. Rat blood for serum preparation was collected via tail vein draw. Biospecimens were stored at -80C until assay.
N-ter titin ELISA
Urinary amino-terminal titin fragments were quantified using antibodies that are specific for a peptide comprising amino acid residues 1-110 of titin . The following assay recognizes human, mouse and rat urinary N-ter titin. Anti-titin clone 2F12 (Abnova, Taipei, Taiwan) was coated overnight at 2ug/ml in bicarbonate buffer on Costar 3225 black plates. 96-well ELISA plates were washed and blocking buffer containing 5% BSA in PBS was added for a minimum of 2 hours at room temperature while shaking. The recombinant titin 1-110 standard (with an Nterminal glutathione S-transferase (GST)-tag, Abnova) or urine diluted in 1%BSA in PBS was added and incubated for at least 2 hours at room temperature while shaking. The alkaline phosphatase (AP) conjugated anti-titin clone 6H5 antibody (Lightning-Link, Abnova) was added at 2000X dilution and the reaction was incubated to equilibrium overnight at 4C while shaking.
The plate was decanted and washed four times with PBS containing 0.05% Tween20. After the final wash, the plate was decanted and blotted to remove all liquid, alkaline phosphatase substrate (Applied Biosystems T2214) was added and the plate read on an EnVision ELISA plate reader (Perkin Elmer, Waltham, MA). Other antibody pairs were used, e.g., anti-titin clone 7D3
and clone 2B3 (Abnova), with similar results, and all results in the present study were with the 2F12/6H5 pair. Urine samples from DMD patients and mdx mice had to be diluted typically 50
fold to bring N-ter titin values to the middle of ELISA standard curves. Urine from healthy controls was diluted 2 fold. The titin 1-110 standard was performed in triplicate and samples were typically performed in duplicate per ELISA plate.
N-ter titin ECL assay
The ELISA assay described above was adapted to the 384-well ECL format using the same binding and detection antibodies but utilizing a tenth of the sample size required by ELISA. The main difference from the ELISA format is the use of a sulfo-tagged instead of APtagged 6H5 detection antibody (MSD GOLD SULFO-TAG NHS-Ester), MA6000 384 HB plates, and the Sector S 600 plate reader (all from Meso Scale Discovery, Rockville, MD 
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Urine specific gravity
Specific gravity of urine samples was determined using an analog refractometer (Atago UriconN, Catalog # 2720; NSG Precision Cell, Inc., Farmington, NY).
Statistics
Statistical analyses were conducted using SAS v9.2 and GraphPad Prism v7.02. Unless noted otherwise, one way ANOVA followed by Dunnett's multiple comparisons test (two-tailed) was used to assess statistical significance in data comparisons.
Results
ELISA assay development and qualification for use in human DMD urine
Several commercially available monoclonal antibodies that are reported to recognize Nter titin (2F12, 6H5, 7D3 and 2B3) were compared to determine the best pair for ELISA assay an unrelated antigen (anti-amyloid antibody 4G8) (Fig. 1A) . Furthermore, when acid-eluted from the immunosorbent beads, the immunodepleted antigen was detected on Western blot using 6H5, and migrated to the same ~25kDa position as the antigen in the native DMD urine starting material (Fig. 1B) . The molecular weight of this N-ter titin fragment is the same as that seen by Rouillon et al in human DMD urine [5] . As a control for Western blot visualization of N-ter titin, the titin 1-110 standard was also run in an overloaded lane to reveal the expected MW and a small contamination with N-ter titin degradation fragments, but not the ~25 kDa fragment seen in the DMD patient urine samples (Fig. 2B ).
Quantification of urinary N-ter titin in DMD subjects and age-matched normal subjects
Normalization to urine creatinine content is typically used to account for trivial differences, in subject hydration, in urine analyte concentration. However, DMD subjects have extensive skeletal muscle damage resulting in abnormally low urine creatinine levels, and therefore urine creatinine cannot be used for normalization of urine analyte content (nor indeed as a measure of kidney function) [8] . We therefore used urine specific gravity for normalization, which has been compared extensively to normalization to urine creatinine and found to be essentially equivalent in healthy subjects [9] . The following equation was used for normalization of urinary N-ter titin to mean specific gravity, taken from Cone, et al [9] , based on the classic equation of Levine and Fahy [10] :
Titin (ng/ml) SG normalized = Titin (ng/ml) specimen X (SG reference -1)/(SG specimen -1),
where specific gravity (SG) reference = 1.0200 DMD patient and control urine specific gravity did not differ significantly (Table 1) and together had a mean of 1.022 ± 0.002, in agreement with the reference mean of 1.0200 used by
Cone, et al [9] . Table 1 shows the age, mutations and ambulatory status of the subjects, and specific gravity of urine samples. in from -32 to 133% change in the individual urinary N-ter titin levels compared to the values without normalization. This does not significantly change the cross-sectional data means, but does decrease variability and is included to indicate potential value of normalization of urine analytes to mean specific gravity in future application to longitudinal studies (Table 1 ). Fig. 2 shows the urinary N-ter titin levels in urine samples from 7 DMD subjects and 7 age-matched normal subjects, measured by ELISA, and normalized to mean specific gravity. There was a significant 365-fold increase in mean urinary N-ter titin excretion in DMD vs age-matched normal urine samples (365.4 ± 65.0 vs 1.0 ± 0.4 ng/ml; n = 7; P = 0.0001; TTEST). It should also be noted that this is a limited set of 7 DMD and 7 healthy control urine samples; dividing the greatest DMD value by the lowest healthy value, and vice versa, yields 6720-fold and 58-fold as the range of titin elevation observed in DMD patients relative to healthy controls. There was no relationship between urinary N-ter titin excretion and age of subject or ambulatory status in this limited sample set (Table 1) .
Natural history of urinary N-ter titin in mdx mice and age-matched wild type mice
Due to the 93% homology of the amino acid sequence between human and mouse titin , the human N-ter titin assay also detected mouse N-ter titin. To explore the relationship of disease progression with N-ter titin we employed a mouse model of DMD. We measured urinary N-ter titin in mdx and age-matched WT control mice ranging from 2 to 19 weeks of age.
We examined urinary N-ter titin excretion in two overlapping longitudinal cohorts of mice from which we obtained weekly urine samples, and for which the composite data is shown in Fig. 3 . Urinary N-ter titin was below the lower limit of quantitation (LLOQ; 0.4 ng/ml for ELISA) in WT mice of any age measured by ELISA (not shown). At 2 weeks of age, the concentration of urinary N-ter titin levels in mdx mice was 82 ± 11.8 ng/ml, but by 3 weeks of age and later, a significantly greater elevation of urinary N-ter titin was observed (Fig. 3 ). This pattern of urinary titin excretion mirrors the onset of systemic skeletal muscle fiber injury seen in mdx mice at approximately 3 weeks of age [11, 12] . Normalization of urinary N-ter titin to mean specific gravity was not performed for mouse samples in this study due to limited volumes (typically < 10 ul) of mouse urine samples collected. This study was also limited because for some time points not every mouse produced a spot urine sample. To assess the statistical significance of urinary titin elevation after the two week time point, we used the False Discovery Rate analysis [13] of data pairs for those animals for which a 2 week N-ter titin value and a value from a subsequent time point was available. This analysis showed that the elevation in urinary titin was significantly greater than the week 2 level at weeks 3, 4, 5, 6 (P = 0.01, 0.02, 0.05, 0.001).
To better quantify the increase in urinary N-ter titin in mdx mice, we adapted the ELISA to a more sensitive ECL assay using the same binding and detection anti-N-ter titin antibodies and performed a cross-sectional study of mdx mice of different ages. The ECL assay (Fig. 4A) in 384-well format required one tenth of the ELISA sample volume (enabling use of a lower sample dilution to aid detection in low signal samples), with a lower background and greater dynamic range (linear up to 150 ng/ml vs ~20 ng/ml) compared to the ELISA (Supplemental Fig.   1A ). Despite the increase in sensitivity, urinary N-ter titin levels in WT mice remained below the LLOQ of the ECL assay. Fig. 4B shows urinary N-ter titin excretion determined by ECL assay in mdx mice ages 2 to over 70 weeks. As in the longitudinal study, low urinary N-ter titin levels at two weeks were followed by significantly higher elevation at 5-36 weeks, with a peak at 4152 ± 1170 ng/ml (24-fold above the 2 week level, P < 0.001) at 24 weeks, and diminishing levels in the oldest mice over 70 weeks (range of 77-83 weeks) of age.
We measured serum skeletal muscle TnI in blood samples from the same cohorts (Fig.   4C ). In contrast to urinary N-ter titin, we were able to measure low serum skeletal muscle TnI levels in WT mice (3.7 ± 0.3 ng/ml across all ages tested; no significant differences among ages).
Two-week-old mdx mice had significantly higher (21-fold) serum skeletal muscle TnI levels versus 2-week-old WT mice. A similar expression pattern to urinary N-ter titin with mdx mouse age was seen with serum skeletal muscle TnI, with significantly higher elevation at peaking at 1195 ± 164 ng/ml (19-fold above the 2 week mdx mouse level and a 299-fold increase over WT mice, P < 0.001) at 24 weeks of age, and declining at 70+ weeks of age.
We also measured serum CK in blood samples drawn from the same cohorts (Fig. 4D ).
As with skeletal muscle TnI, and in contrast to urinary N-ter titin, serum CK was quantifiable in WT mice (773 ± 101 ng/ml for all ages tested; no significant differences among ages). Twoweek-old mdx mice had significantly higher (4-fold) serum CK levels versus 2-week-old WT mice. As for urinary N-ter titin and serum skeletal muscle TnI, serum CK in mdx mice was significantly elevated with age over WT levels, peaking at 25023 ± 5299 U/l (14-fold above the 2 week level and a 33-fold increase over WT, P < 0.001) at 24 weeks of age, and declining at 70+ weeks of age.
Urinary N-ter titin levels were significantly correlated with serum skeletal muscle TnI levels (R = 0.76, P < 0.0001; Fig. 5A ) and CK levels (R = 0.63, P < 0.0001; Fig. 5B ). Serum
TnI and CK levels were also significantly correlated (R = 0.79, P < 0.0001; Fig. 5C ).
Effect of corticosteroid treatment on urinary N-ter titin, serum skeletal muscle TnI and exercise performance in mdx mice
Corticosteroids improve muscle function and lower serum CK in mdx mice [14] , and corticosteroid treatment has recently been approved for DMD patients and is associated with increased muscle strength [15] . In order to explore the potential for urinary N-ter titin as a dynamic marker of muscle status, mdx mice were treated with oral prednisolone (0.75 or 5mg/kg) for 5 days per week for 6 weeks. Mice were assessed for urinary N-ter titin concentrations and serum TnI concentrations at 5 weeks, and functional improvement using a run-to-exhaustion exercise performance protocol at 6 weeks (the one week delay in functional test relative to biospecimen collection was to avoid any trivial interference from the biospecimen collection procedure). Compared to vehicle treatment, prednisolone treatment caused significant decreases in urinary N-ter titin (Fig. 6A ) and serum skeletal muscle TnI (Fig. 6B) , and was associated with significantly improved exercise performance in mdx mice, (Fig. 6C ).
Urinary N-ter titin elevation in Dmd mdx rats
Urinary N-ter titin excretion was examined using the ECL assay in WT and Dmd mdx rats at 5 months of age. In contrast to WT mice, the level of urinary N-ter titin excretion in WT rats was quantifiable, and was 3.0 ± 0.6 ng/ml (Fig. 7A ). Similar to mdx mice and DMD patients, the level rose dramatically in Dmd mdx rats to 1652.5 ± 405.7 ng/ml, a 556-fold increase over WT (P = 0.002) (Fig. 7A) . Serum levels of skeletal muscle TnI were also significantly higher in Dmd mdx rats versus WT rats (217 ± 41 versus 15.5 ± 6.3 ng/ml, P < 0.001; 14-fold increase) (Fig. 7B) .
The fold-increase in urinary N-ter titin was significantly greater than the fold increase in serum TnI (P = 0.01).
Conclusions and Discussion
New ELISA and ECL assays for an N-ter titin fragment were developed and qualified for use in detection of urinary N-ter titin excretion. The molecular weight of the N-ter titin fragment detected in our studies was similar to the 25 kDa fragment reported in Western blot studies by Roullion et al [5] . Quantification with our immunoassays revealed a profound (365-fold)
elevation of urinary N-ter-titin excretion in DMD patients compared to age-matched healthy controls. We also measured large increases in urinary N-ter titin excretion in the mdx mouse model of DMD, and decreases in response to corticosteroid treatment, associated with improved exercise performance. The dynamic changes associated with functional improvement in this experiment suggest that urinary N-ter titin may be a valid indicator of general muscle health, especially in DMD. We were not able to quantify the fold increase in urinary N-ter titin excretion over WT mice due to lack of detectable urinary N-ter titin in WT controls with either ELISA or ECL assay. However, we were able to quantify urinary N-ter titin in rat WT controls with our ECL assay and demonstrate a 556-fold increase in Dmd mdx rats, similar to the increase seen in humans DMD subjects. Our working hypothesis is that in healthy subjects there is a baseline turnover of skeletal muscle that yields release of low levels of titin from skeletal muscle and appearance of the N-ter titin degradation fragments in urine. In contrast, the dramatic increase in urinary N-ter titin excretion seen in DMD likely reflects increased systemic skeletal muscle damage and regeneration, and decreased sarcolemmal integrity, both of which are central to skeletal muscle dysfunction in this disease.
The concept of a normal, albeit very low, level of titin turnover is supported by the ability of our sensitive ELISA assay to detect basal urinary N-ter titin excretion in heathy human, and ability of our improved ECL platform to detect titin in urine of age-matched WT rat controls.
Titin is rapidly incorporated into detergent-insoluble structures soon after its synthesis and has a half-life of about 3 days, and thus is a slow-turnover structural protein [16] . Interestingly, this basal level of urinary titin in healthy controls was not seen by Roullion et al using Western blots for detection [5] in humans, mice or dogs, which we assume is due to the reduced sensitivity of the Western blot versus immunoassay. We believe the inability to measure baseline urinary Nter titin excretion in WT mice is due to the relatively low total skeletal muscle mass, resulting in a level of titin release below the threshold required for titin detection in urine. In contrast, the larger muscle masses of rats and humans contribute sufficient basal titin turnover to enable detection in urine.
Elevation in urinary N-ter titin in the natural history of disease in the mdx mouse appears to reflect the onset of muscle injury and regeneration. In the present study, very low but quantifiable levels of urinary N-ter titin excretion were detected in two week old mdx mice, compared to a large increase at 3 weeks of age. This temporal profile is consistent with the well documented sudden onset of the severe muscle injury phase of skeletal muscle involvement in mdx mice at 3 weeks of age [11] . The sudden elevation in urinary N-ter titin excretion at 3 weeks of age was also noted by Roullion et al, though their methods did not permit recognition of the signal at 2 weeks of age [5] . This observation of a dramatic urinary titin elevation at the onset of the severe muscle injury phase of disease may translate to a similar phenomenon in DMD in humans. It will be important in future studies to define the age of onset of titin elevation in DMD.
The precise mechanism of titin degradation, release to circulation and appearance of fragments in urine is unclear. There is precedence in DMD for extensive degradation of titin within skeletal muscle before release to the circulation. Using Western blot techniques, Matsumura et al showed degradation of titin in DMD muscle biopsies is greatly increased in DMD patients ~5 years of age [2] , coincident with onset of severe systemic skeletal muscle involvement and sarcolemmal disruption (reviewed in [12] ), and analogous to the onset of disease at 3-4 weeks of age in mice. A serine protease in DMD skeletal muscle [17] , and a metalloprotease in cardiomyocytes [18] , have been implicated the degradation of the skeletal muscle and cardiac forms of titin, respectively. Interestingly, in spite of the massive size, titin may exchange between soluble and insoluble sarcomeric pools in cardiomyocytes [19] . If such pools also exist in skeletal muscle we speculate that distribution to soluble sarcomeric pools may increase exposure to proteases, particularly in the setting of accelerated injury and regeneration in DMD. Leakage of muscle proteins due to sarcolemma disruption in DMD [12] would be expected to contribute to the appearance of titin degradation products in the circulation. A proteomics study by Oonk et al revealed titin in serum of DMD patients but not healthy controls [6] . The precise tissue sites (e.g, muscle, blood, kidney) for further degradation of titin are not known.
We have not systematically explored urinary N-ter titin excretion using our sensitive immunoassays in other neuromuscular diseases or muscle wasting conditions. Matsumura et al found progressive and relentless degradation of titin in Western blots prepared from muscle biopsies in DMD subjects, and much less degradation in Becker muscular dystrophy, but not in normal controls [2] . They found minimal titin degradation in muscle biopsies from patients with Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, limb girdle muscular dystrophy or myotonic dystrophy [3] , with the caveat that a systematic study across age and disease severity has not been done. Interestingly, this same group found significant titin degradation in Fukuyama type congenital muscular dystrophy as early as 5-8 months of age, suggesting an earlier appearance of titin degradation in a disease characterized by myofibrillar inclusions compared with the muscle degeneration and replacement by fatty and fibrotic tissue observed in DMD [3] . Rouillon et al detected N-ter titin fragment by Western blot in urine from patients with limb-girdle muscular dystrophies and in urine from one of two patients with Becker muscular dystrophy, in addition to DMD patient urine previously mentioned, but not in urine from patients with spinal muscular atrophy [5] . It will be important in future work to quantify urinary titin excretion in other genetic and acquired neuromuscular diseases, as well as in skeletal muscle wasting disorders such as cachexia associated with chronic inflammatory disorders or cancer, sarcopenia associated with aging.
We considered several options for normalization of human urinary N-ter titin excretion to account for differences in urine hydration status, including urine creatinine content, urine total protein content and urine specific gravity. Urine creatinine content is most commonly the analyte of choice for normalization, as it is an inert product of non-enzymatic creatine metabolism, chiefly from skeletal muscle. Furthermore, creatinine is produced by the body at a constant rate per day, and has been related in spot urine samples to urine flow and kidney function [20] . However, creatinine is not suitable for use in DMD subjects, for either normalization of urine analytes or assessments of kidney function, due to abnormal urine creatinine content associated with systemic skeletal muscle damage [8] . Urine total protein content is highly variable, exhibiting a wide normal range from 0-200 ug/ml [21] and in our hands tends to be on the <100 ug/ml end of this range (data not shown). Furthermore, urine protein is derived from many tissues and subject to differential metabolism, and therefore is not a good candidate for a basis of normalization. Specific gravity is easily measured using a refractometer, and equivalence to urine creatinine for normalization of urine analytes such as in drug abuse testing is well documented [9] . Mean specific gravity for DMD and healthy age-matched subjects in the present study were in agreement with the broadly accepted 1.0200
reference mean for human urine [9] . While having little effect on the cross-sectional single time point analysis of DMD patient and healthy control urine samples in this study, normalization to mean specific gravity reduced variability in urinary N-ter titin concentration. The range for specific gravity for individual urine samples in this study was from 1.009 to 1.031, which resulted in from -32% to +133% change in individual samples after normalizing urinary titin excretion levels to mean specific gravity. Thus, normalization of trivial N-ter titin content differences due to urine flow and hydration status should offer an important increase in precision and accuracy for longitudinal monitoring of therapeutic approach change from baseline.
The list of serum proteins arising from skeletal muscle damage and leakage, with potential DMD biomarker value, is increasing [22] . Our work with mdx mice at different ages afforded the opportunity to compare urinary titin concentrations with the classic serum marker of DMD muscle damage, CK [23] , and a more recently developed measure of muscle damage in DMD coming into greater use, serum skeletal muscle TnI [24] . Both serum markers mirrored the changes seen with urinary N-ter titin excretion with mdx mouse age, and serum markers were significantly correlated with urinary N-ter titin concentrations. The correlation between the two serum markers was stronger than the correlation between urinary N-ter titin and either serum marker alone. We speculate the correlation between urinary N-ter titin and the serum markers may have been improved if we were able to collect sufficient urine sample volume to permit normalization to mean specific gravity. It was interesting to note the decrease in all three biomarkers concentrations at the latest ages of our cohorts (over 70 weeks). Importantly for translational context, the decrease in muscle damage markers with age has been reported previously in DMD, as demonstrated and reviewed recently by Birch et al in a study of the application in humans of ECL assays for rat biomarkers owing to amino acid sequence conservation [24] . This group speculates both decreased muscle mass and ambulation with age may affect muscle damage biomarker levels, though more work is needed to define precise mechanisms.
Though we have not yet performed a natural history study in rats, our data in 5-month-old Dmd mdx rats is consistent with the mdx mouse. Dmd mdx rats have previously been shown to have significant ~10-fold increases in serum CK [7] . Here we additionally show a significant elevation in concentration of both urinary N-ter titin and serum skeletal muscle TnI over WT levels. Interestingly, the 556-fold increase in urinary N-ter titin was significantly higher than the 14-fold increase in serum sTnI, suggesting that the dynamic range of the response of the urinary N-ter titin biomarker to the dystrophic condition is greater than for sTnI. We could not confirm this precise determination in mdx mice since WT urinary N-ter titin levels were below LLOQ.
Likewise, we did not have serum samples from our DMD patient donors, so we could not directly compare fold-increases in serum skeletal muscle TnI with urinary N-ter titin in this study. Similarly, Burch et al reported that healthy controls had serum skeletal muscle TnI concentration below LLOQ, and thus could not make precise fold-increase determinations in DMD patients [24] . Thus, a potential advantage of the urinary N-ter titin biomarker, in addition to a dramatic signal response to dystrophic muscle disease, is precise measurement of baseline levels in healthy controls.
Roullion et al found mdx mouse urine Western blot band intensities trended to be greater 3h after a brief downhill running exercise protocol compared to 7 days before exercise [5] . In our hands, the simple manipulation of a gentle manual restraint of mdx mice to collect droplets of urine samples was sufficient to induce a transient 5-10-fold elevation in urinary N-ter titin excretion within 3 hours post-handling, returning to baseline within 48h, with no increase seen in non-restrained controls (data not shown). This observation confounds attempts to examine the relationship between immediate skeletal muscle damage and urinary titin excretion. More work is needed to determine the contribution to transient urinary titin increase of immediate skeletal muscle damage.
The current study has several limitations. The number of DMD subject urine samples
was not large enough to investigate effects of age, ambulatory state, disease severity, or treatment status (eg, steroid use) on urinary N-ter titin elevation. However, the current work enables future studies of these important clinical parameters. In mice, urine sample volume was too small to allow refractometry and thus all mouse (and rat) data are reported without normalization to mean specific gravity; normalization would be expected to reduce variability, particularly for longitudinal studies. Also relating to our mouse studies, the biomarker correlations are with relatively small sample size (n = 8) and the magnitude of the linear correlations may be influenced by subsets of points with high concentrations. The titin N-terminal 110 amino acids are conserved in striated muscle and therefore our N-ter titin immunoassays should also detect titin from cardiac muscle. We have made the assumption that the vast majority of the titin we detect in urine is derived from skeletal muscle owing to the vast excess of skeletal over cardiac muscle mass. We have not yet adapted these immunoassays for use in serum or muscle biopsy extracts, as initial attempts suggest matrix effects reduce immunoassay sensitivity. A serum/muscle assay would be useful in defining the comprehensive metabolism of skeletal muscle titin in health and disease.
Taken together, our data suggest urinary N-ter titin measured in a spot urine sample is a robust and dynamic translational biomarker of the DMD phenotype. Increases in urinary N-ter titin are consistent across rodent models lacking dystrophin as well as in DMD patients. Urinary N-ter titin has potential as a non-invasive and facile diagnostic as well as a longitudinal measure of muscle damage in DMD therapeutics development and therapy. While the preliminary work in this study is suggestive, future work is required to establish urinary N-ter titin elevation as a validated surrogate marker of skeletal muscle quality and function in DMD. Cross-sectional study of urinary N-ter titin levels measured by ECL assay in mdx and age-matched WT mouse cohorts. Note that all WT urinary N-ter titin levels were below lower limit of quantitation. (***P < 0.001 versus 2 week mdx, n = 8, One way ANOVA followed by False Discovery Rate analysis). C. Cross-sectional study of serum skeletal muscle TnI levels measured by ECL assay in mdx and age-matched WT mouse cohorts (***P < 0.001 versus 2 week mdx, n = 8, Two way ANOVA followed by False Discovery Rate analysis). D. Cross-sectional study of serum CK levels measured in mdx and age-matched WT mouse cohorts (***P < 0.001, **P < 0.01, versus 2 week mdx, n = 8, Two way ANOVA followed by False Discovery Rate analysis). DMD, Duchenne muscular dystrophy; N-ter, amino-terminal; **, P < 0.01 versus control mean (TTEST); ****, P = 0.0001 versus control mean (TTEST).
